The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. VivoSim Labs's Revenue for the
three
months ended in Dec. 2025 was €0.02 Mil. VivoSim Labs's average Accounts Receivable for the
three
months ended in Dec. 2025 was €0.03 Mil.
Hence, VivoSim Labs's Receivables Turnover for the
three
months ended in Dec. 2025 was 0.80.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
VivoSim Labs Receivables Turnover Related Terms
VivoSim Labs Receivables Turnover Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4OR vs SLXN, CDT, CLDI: Receivables Turnover Comparison
For the Biotechnology subindustry, VivoSim Labs's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a Receivables Turnover of 0.80 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on VivoSim Labs and its competitors. According to the industry distribution chart, VivoSim Labs ranks #472 out of 846 companies in the Biotechnology industry, placing it in the top 55.8%.
Is VivoSim Labs' Receivables Turnover too high?
VivoSim Labs' current Receivables Turnover is 0.80. The Biotechnology industry median Receivables Turnover is 5.29. VivoSim Labs' value of 0.80 is 84.9% below this industry median. Based on the distribution chart, VivoSim Labs ranks #472 out of 846 companies in the Biotechnology industry, which is below the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Receivables Turnover compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #472 out of 846 companies for Receivables Turnover. This places VivoSim Labs in the lower half of its industry. The industry median Receivables Turnover is 5.29. VivoSim Labs' value of 0.80 is 84.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 846 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current Receivables Turnover of 0.80 is 84.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on VivoSim Labs and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current Receivables Turnover is 0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Receivables Turnover of 0.80. The stock's GF Value™ is €8.71, compared to a current price of €3.49 — trading 59.9% below its estimated fair value. The current Receivables Turnover is 0.80 and 84.9% below the Biotechnology industry median of 5.29. VivoSim Labs' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Receivables Turnover is 0.80 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 59.9% below its estimated GF Value™ of €8.71.
Key valuation signals for FRA:4OR:
Receivables Turnover: 0.80
GF Value™: €8.71 vs. price of €3.49 (59.9% below fair value)
Industry Position: 84.9% below the Biotechnology median (#472 of 846)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
38GF Score
Get the complete analysis for FRA:4OR
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
